<DOC>
	<DOCNO>NCT01090154</DOCNO>
	<brief_summary>The purpose study determine Cimzia ( certolizumab pegol ) effective treatment patient Ulcerative colitis .</brief_summary>
	<brief_title>Study Cimzia Treatment Ulcerative Colitis</brief_title>
	<detailed_description>Ulcerative colitis ( UC ) chronic inflammatory bowel disease often result significant morbidity well impairment quality life . Cimzia ( certolizumab pegol ) , inhibitor tumor necrosis factor-alpha , effective treatment Crohn 's disease , similar inflammatory bowel disease . The aim study determine Cimzia effective induction maintenance response/remission patient moderate severe Ulcerative colitis .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Inclusion Criteria 1 . Adults age 1875 year 2 . Established diagnosis UC ( routine clinical , radiologic , endoscopic , histologic criterion ) least 3 month duration 3 . Moderate severe active disease , define Mayo score &gt; 6 endoscopic subscore &gt; 2 4 . Ability understand study protocol treatment , willingness comply study requirement , ability provide inform consent 5 . No history prior tuberculosis ( TB ) , sign symptom active TB , negative Quantiferon gold test PPD chest Xray show active latent TB screening within 6 month prior screen visit . 6 . Screening blood test must meet following criterion : white blood cell count &gt; 3000/µL ( neutrophil &gt; 1500/µL lymphocyte &gt; 500/µL ) , hemoglobin &gt; 8 g/dL , platelet count &gt; 100,000/µL , liver function test &lt; 3 time upper limit normal , serum creatitine &lt; 1.5 mg/dL 7 . Screening stool sample negative Clostriduim difficile , ovum &amp; parasite , aerobic pathogen , include Aeromonas , Plesiomonas , Salmonella , Shigella , Yersinia , Campylobacter , E. coli spp . 8 . Medication use must meet following criterion : 1 . Rectally administer topical 5aminosalicylates ( 5ASAs ) /corticosteroids : must discontinue 1 month prior baseline ; allow study 2 . Oral 5ASAs : allow stable dose least 2 week prior baseline ; remain stable dose study 3 . Antibiotics UC : must discontinue 1 month prior baseline ; allow study 4 . Antidiarrheals : must discontinue 2 week prior baseline ; allow study 5 . Corticosteroids : allow Prednisone dose equivalent 20 mg/d less , stable 2 week prior baseline ( dose/taper study discuss ) ; budesonide allow dose less equal 9 mg/day stable dose 2 week prior baseline 6 . 6Mercaptopurine ( 6MP ) /Azathioprine/Methotrexate : allow least 8 week , stable dose least 4 week prior baseline ; remain stable dose study 7 . AntiTNF therapy : Patients must naive CZP . Patients may prior exposure antiTNF therapy ( e.g. , infliximab , adalimumab , golimumab ) , however patient primary nonresponders one antiTNF medication exclude . Patients must prior antiTNF medication least 8 week prior baseline . 8 . Integrin inhibitor therapy : Patients may prior exposure integrin inhibitor therapy ( e.g. , vedolizumab ) . Patients must integrin inhibitor therapy least 8 week prior baseline . 9 . Cyclosporine : patient previously receive Cyclosporine UC must prior Cyclosporine therapy least 4 week prior baseline . 10 . Any medication treatment Ulcerative colitis investigational medication : must discontinue least 1 month 5 halflives ( whichever longer ) baseline ; allow study 9 . Female subject childbearing potential must agree practice effective method birth control study 12 week last dose study drug . Acceptable method include : oral contraceptive , transdermal contraceptive , injectable contraceptive , implant , intrauterine device , barrier method spermicide , surgical sterility . Exclusion Criteria 1 . Diagnosis Crohn 's disease indeterminate colitis , clinical finding suggestive Crohn 's disease 2 . Fulminant disease , toxic megacolon , anticipated imminent colectomy 3 . Presence ileal pouch ostomy 4 . Pregnancy , desire become pregnant follow 18 month , breast feeding 5 . Surgery kind within 2 month screen anticipate surgery kind study 6 . Anticipated imminent hospitalization medical condition 7 . Active ongoing infection kind 8 . Current use total parenteral nutrition 9 . History : 1 . Congestive heart failure significant coronary artery disease ( include myocardial infarction , percutaneous coronary intervention , coronary artery bypass within 6 month screen ) 2 . Cancer 3 . Colonic dysplasia ( except sporadic adenoma ) . Also , patient find colonic dysplasia time study withdrawn study . 4 . HIV , chronic active hepatitis B C , patient consider high risk infection ( obtain history/detailed medical chart review except hepatitis B , test blood sample ) 5 . Prior opportunistic infection within 6 month screen prior opportunistic infection antiTNF therapy 6 . Hepatic disease ( cirrhosis , chronic active hepatitis , LFT abnormality ) 7 . Renal insufficiency ( see ) 8 . Clinically important pulmonary disease ( determine subjectively ) 9 . Demyelinating disease 10 . Organ transplantation , include bone marrow ( except corneal ) 11 . Lymphoproliferative disorder SAMPLE SIZE CALCULATION</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>UC</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>